- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ProKidney GAAP EPS of -$0.13, revenue of $0.2M | 1 | Seeking Alpha | ||
| Mo | PROKIDNEY CORP. Loss At -$16.73 Mln In Q1 | 1 | RTTNews | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| Mo | ProKidney Reports First Quarter 2025 Financial Results and Business Highlights | 301 | GlobeNewswire (Europe) | Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional... ► Artikel lesen | |
| Mo | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Mo | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | PROKIDNEY CORP. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.03. | ProKidney GAAP EPS of -$0.62 | 2 | Seeking Alpha | ||
| 17.03. | PROKIDNEY CORP. Full Year Loss Increases | - | RTTNews | ||
| 17.03. | ProKidney Reports Full Year 2024 Financial Results and Business Highlights | 130 | GlobeNewswire (Europe) | Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing... ► Artikel lesen | |
| 21.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.11.24 | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting | 141 | GlobeNewswire (Europe) | FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed... ► Artikel lesen | |
| 09.08.24 | ProKidney Reports Business Updates and Second Quarter 2024 Financial Results | 273 | GlobeNewswire (Europe) | Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT... ► Artikel lesen | |
| 10.06.24 | ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates | 187 | GlobeNewswire (Europe) | Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVOSIM LABS | 1,930 | 0,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,750 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,364 | -2,67 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial Results | CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,073 | -100,00 % | Enveric Biosciences GAAP EPS of -$1.22 | ||
| VERRICA PHARMACEUTICALS | 0,530 | -8,63 % | Verrica signals sustainable growth trajectory as YCANTH revenues surpass $3M and Phase 3 milestone looms | ||
| REPARE THERAPEUTICS | 1,320 | +1,15 % | Repare Therapeutics GAAP EPS of -$0.71 | ||
| BIOATLA | 0,427 | 0,00 % | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen | |
| RELMADA THERAPEUTICS | 0,340 | -7,61 % | Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 7,640 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| BOUNDLESS BIO | 1,670 | 0,00 % | Boundless Bio, Inc.: Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights | Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track... ► Artikel lesen | |
| PEPGEN | 1,410 | 0,00 % | PepGen stock price target cut to $14 from $16 by H.C. Wainwright | ||
| QIAGEN | 37,615 | +0,36 % | ANALYSE-FLASH: UBS belässt Qiagen auf 'Neutral' - Ziel 48 Dollar | ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| TEMPUS AI | 62,60 | 0,00 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,075 | 0,00 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut, USA | Datum der Anmeldung:08.05.2025Aktenzeichen:B3-54/25Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut... ► Artikel lesen | |
| EVOTEC | 6,976 | -1,22 % | Evotec-Aktie mit leichten Kursgewinnen (7,086 €) | Im Plus liegt derzeit das Wertpapier von Evotec . Zuletzt zahlten Investoren für das Wertpapier 7,09 Euro. Am deutschen Aktienmarkt hat sich heute die Evotec-Aktie zwischenzeitlich um 2,99 Prozent verteuert.... ► Artikel lesen |
Das Unternehmen PROKIDNEY CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +11,20 % bei einem Aktienkurs von 0,858 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.